Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
refunds apply to medical disqualification scenarios only
FDA approved a new indication for semaglutide (Wegovy) to reduce the risk of cardiovascular death, myocardial infarction, and stroke in adults with CVD and either obesity or overweight (Lincoff et al., 2023)
This creates the core investment question: Is it deep value or a falling knife/value trap? Ratios suggest deep value, with a forward earnings yield of ~12%, a dividend yield near 7%, and a Price-to-Book ratio near 1, implying pessimism is already priced in
Conclusion The timing of glutathione supplementation can influence its benefits
US$ 29.92
US$ 26.22
US$ 23.79
US$ 20.11
US$ 27.41
